Elevated ovarian pentraxin 3 in polycystic ovary syndrome

Jiexue Pan1,2,3,4 · Chengliang Zhou1,3 · Zhiyang Zhou1,2,3 · Zuwei Yang1,2,3 · Tiantian Dai1,3 · Hefeng Huang1,2,3,5 · Li Jin1,2,3,4

Received: 28 December 2020 / Accepted: 7 February 2021 / Published online: 16 February 2021 © The Author(s) 2021

Abstract

Purpose Pentraxin 3 (PTX3) plays a crucial role in cumulus expansion and fertilization. The ovarian PTX3 level in polycystic ovary syndrome (PCOS) remains uncertain. In the present study, we investigated the follicular PTX3 levels and found the influence of reproductive hormones on ovarian PTX3 concentration.

Methods This study was based on 204 healthy-weight women (102 PCOS and 102 normal ovulating subjects) undergoing in vitro fertilization (IVF). Follicular fluid (FF) was collected during oocyte retrieval. The PTX3 levels and other hormone levels in FF samples were analyzed by enzyme-linked immunosorbent assay (ELISA).

Results The PTX3 level in the follicle was significantly higher in the healthy-weight PCOS women than controls. Positive correlations were found between ovarian PTX3 level and the existence of PCOS, cycle length, basal LH to FSH ratio and TT in serum, antral follicle count, and ovarian insulin and androgen level, and inverse correlations with the basal serum PRL and ovarian SHBG. In multivariant linear regression analysis, the presence of PCOS diagnosis, participants' basal LH to FSH ratio, and ovarian androstenedione level were the main predictors of ovarian PTX3 level among the enrolled subjects.

Conclusion Elevated ovarian PTX3 level supports the low-grade chronic inflammatory state in the follicles of PCOS. The existence of PCOS, disturbed pituitary gland, and ovarian hyperandrogenism might also be related to this state of low-grade chronic inflammation and could be a subject of further study.

Keywords Polycystic ovary syndrome · PTX3 · Hyperandrogenism · Follicular fluid · Innate immunology

Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies, afflicting females of reproductive age, with an estimated prevalence of 5–19.9% according to different diagnostic criteria [1, 2]. It is characterized by hyperandrogenism, oligo-/anovulation, and polycystic ovarian morphology. Metabolic dysfunction in PCOS includes increased incidence of insulin resistance, hyperinsulinemia, dyslipidemia, and cardiovascular diseases. Detailed pathogenesis of PCOS remains to be illustrated. Emerging data suggest that PCOS is a multifactorial disease, and genetic [3], epigenetic [4], and environmental [5] factors could determine individual susceptibility of this condition.

Accumulating evidence suggests that PCOS is a chronic inflammatory disease. The ovaries of women with PCOS exhibit inflammation and fibrosis [6]; the peripheral blood of women with PCOS has reduced numbers of anti-inflammatory regulatory T cells and elevated serum levels of autoantibodies [7], and recent study also indicated the pathogenic role for CD19+ B cells in the development of PCOS [8].
Humoral innate immune molecule pentraxin 3 (PTX3) that belongs to the same superfamily of acute reactants as C-reactive protein (CRP) is a member of the long pentraxin family and has multifunctional properties for its capacity to interact with different types of ligands. In particular, PTX3 plays a non-redundant role in innate immunity by opsonizing selected pathogens [9] and in female fertility [10, 11]. Recent research demonstrated that PTX3 in the circulation is associated with PCOS [12–14], but its role in PCOS is so far inconclusive. Unlike the short pentraxin, PTX3 is produced in the local site of the inflammation, including follicle cells [4], and it is essential for the organization of cumulus oophorus extra-cellular matrix and in vivo fertilization [15, 16]. The PTX3 level in the follicular fluid has not been tested in PCOS women, yet. In this study, we aimed to assess whether the ovarian PTX3 level is altered in PCOS women and analyze the relationships between follicular PTX3 level and clinical and hormonal features.

Materials and methods

Patient selection and sample collection

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of the International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University. All participants provided written informed consent after full explanation of the purpose and nature of all procedures used. One hundred two PCOS patients, diagnosed according to the Rotterdam Consensus (European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine criteria) [6], and one hundred two infertile women with tubal blockage (serving as controls) seeking in vitro fertilization (IVF) treatment were recruited. The control women met the following inclusion criteria: (1) normal ovarian response; (2) menstrual cycle length range between 26 and 33 days; (3) no structural abnormalities of the uterus and ovary was found by vaginal ultrasound and/or laparoscopy; (4) no diseases affecting gonadotropin and sex steroid secretion, clearance, or excretion; (5) no signs of hyperandrogenism; and (6) no polycystic ovary morphology or other morphological abnormalities. And all enrolled subjects met the following inclusion criteria: (1) age between 22 and 37; (2) body mass index (BMI) between 18.5 and 25; (3) both ovaries present; (4) only the subjects undergoing GnRH long agonist protocol or GnRH antagonist protocol were selected; (5) all the participants undergoing intracytoplasmic sperm injection (ICSI) or whose spouse had male infertility factors were excluded. The FF samples were carefully collected from the first aspiration follicle as previously described [4], and only FF samples from one follicle which did not contain any visible blood contamination were used in this study. The FF samples were immediately centrifuged, and the supernatants were stored at −80 °C until further analysis.

Measurement of hormones

The levels of day 3 serum hormones were measured by chemiluminescence immunoassay (CLIA) in the clinical laboratory of International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University. The hormone levels in FFs were detected by enzyme-linked immunosorbent assay (ELISA), including androstenedione (Abcam, Cambridge, UK), total testosterone (TT) (Abcam, Cambridge, UK), sex hormone-binding globulin (SHBG, R&D Systems, Inc. Minneapolis, MN, USA), and insulin (R&D Systems, Inc. Minneapolis, MN, USA). Free androgen index (FAI) was calculated as the ratio of TT (nmol/L)/SHBG (nmol/L) multiplied by 100. The values in FFs were from the individual follicle from each subject.

Measurement PTX3 levels in FF

The concentration of PTX3 in FF was determined using an ELISA kit (R&D Systems, Inc. Minneapolis, MN, USA), according to the manufacturer’s protocol. This assay is a quantitative sandwich enzyme immunoassay technique. The intra- and interassay coefficients of variations were 3.7% and 7.3%, respectively. The assay was performed using FF that had been stored frozen at −80 °C and the PTX3 levels were all measured at the same time using reagents with the same lot numbers to reduce the measurement variability.

Statistical analysis

Statistical analysis is performed using the software SPSS version 24.0 software (SPSS Inc., Chicago, IL, USA). Differences in the demographic and clinical characteristics among the subjects were evaluated by $\chi^2$, $t$ tests, or non-parametric Mann–Whitney $U$ test according to whether the variables were categorical or continuous. The PTX3 distribution was non-normal, so the non-parametric Mann–Whitney $U$ test was applied. The correlations between FF PTX3 levels and other components participating in our study were analyzed using Pearson’s correlation. Multivariate analysis was performed using backward stepwise logistic regression analysis. All tests were two-sided and $P < 0.05$ was considered statistically significant.
Results

Patient demographic data and clinical features

Demographic data and baseline clinical characteristics of cases and controls are shown in Table 1. Enrolled PCOS women and control ones were of comparable age and duration of infertility. The GnRHant protocol was more common among the enrolled subjects. Significant differences between the two groups ($P < 0.05$) could be found in menstrual cycle length, parity, body mass index (BMI), antral follicle count (AFC), serum luteinizing hormone (LH)/follicle-stimulating hormone (FSH) ratio, total testosterone (TT), dehydroepiandrosterone-sulfate (DHEA-S), prolactin (PRL), and estradiol ($E_2$) levels on the third day of menstrual cycle. All these values mentioned above were greater for PCOS group than those in controls except for serum PRL level, which is lower in PCOS women. The PCOS women were more likely to suffer from primary infertility. The fertilization rate of the enrolled PCOS women was significantly lower than that of the controls. The average follicular diameter used for the analysis of FF is 16 mm, and the minimum follicular diameter used to obtain FF is no less than 14 mm. Furthermore, the concentrations of androstenedione, TT, free androgen index (FAI), and insulin in the follicular fluid (FF) were significantly higher in the PCOS group, whereas the sex hormone-binding globulin (SHBG) level was lower.

Ovarian PTX3 levels in PCOS women and controls

As shown in Table 1 and Fig. 1, the ovarian PTX3 level was 8.60 (95% CI: 4.42–18.05) ng/ml and 15.59 (95% CI: 6.64–48.13) ng/ml in control and PCOS women, respectively. We observed a significant elevation of 94% in the mean ovarian PTX3 level from PCOS women ($19.76 ± 1.17$ ng/ml) compared with controls ($10.18 ± 0.47$ ng/ml) ($P < 0.001$).

Table 1  Demographic data and clinical characteristics of IVF patients, between control and PCOS groups

| Items                        | Control ($n = 102$) | PCOS ($n = 102$) | $P$ value |
|------------------------------|--------------------|-----------------|-----------|
| Age                          | 29.98 ± 0.36       | 29.17 ± 0.35    | 0.108     |
| Body mass index (kg/m$^2$)   | 21.39 ± 0.21       | 22.02 ± 0.21    | 0.040     |
| Cycle length (days)          | 28.95 ± 0.17       | 67.56 ± 4.04    | < 0.001   |
| Duration of infertility (years) | 4.27 ± 0.31       | 4.20 ± 0.38     | 0.927     |
| Parity, $n$ (%)              | 40 (39.22)         | 66 (64.71)      | < 0.001   |
| No previous pregnancy        | 40 (60.78)         | 36 (35.29)      |           |
| Day 3 LH/FSH                 | 0.77 ± 0.02        | 1.35 ± 0.08     | < 0.001   |
| Day 3 TT (nmol/L)            | 0.79 ± 0.03        | 2.00 ± 0.08     | < 0.001   |
| Day 3 DHEA-S (umol/L)        | 6.68 ± 0.21        | 7.95 ± 0.31     | 0.001     |
| Day 3 PRL (ng/ml)            | 15.53 ± 0.57       | 13.81 ± 0.55    | 0.031     |
| Day 3 $E_2$ (pmol/L)         | 135.03 ± 4.06      | 159.24 ± 6.95   | 0.003     |
| AFC                          | 10.82 ± 0.23       | 24.59 ± 0.26    | < 0.001   |
| Protocols, $n$ (%)           | 22 (21.6)          | 15 (14.7)       | 0.203     |
| GnRHa long                   | 80 (78.4)          | 87 (85.3)       |           |
| GnRHant                      | 72.84 ± 2.16       | 61.38 ± 2.21    | < 0.001   |
| Androstenedione (ng/ml) in FF| 6.27 ± 0.34        | 8.94 ± 1.01     | 0.013     |
| TT (ng/ml) in FF             | 5.22 ± 0.22        | 9.17 ± 0.55     | < 0.001   |
| SHBG (nmol/L) in FF          | 57.17 ± 1.10       | 51.86 ± 1.32    | 0.002     |
| FAI in FF                    | 32.50 ± 1.39       | 68.20 ± 5.96    | < 0.001   |
| Insulin (mU/L) in FF         | 38.80 ± 1.66       | 50.43 ± 2.10    | < 0.001   |
| PTX3 (ng/ml) in FF           | 8.60 (6.48–13.52)  | 15.59 (11.92–23.10) | < 0.001 |

Day 3, the third day of spontaneous menstrual cycle; $LH$, luteinizing hormone; $FSH$, follicle-stimulating hormone; $TT$, total testosterone; $DHEA-S$, dehydroepiandrosterone-sulfate; $PRL$, prolactin; $E_2$, estradiol; $AFC$, antral follicle count; $GnRHa$, gonadotropin-releasing hormone agonist; $GnRHant$, gonadotropin-releasing hormone antagonist; $Gn$, gonadotrophin; $HCG$, human chorionic gonadotropin; $FF$, follicular fluid; $SHBG$, sex hormone-binding globulin; $FAI$, free androgen index; $PTX3$, pentraxin 3. Values are presented as mean ± SE or median (lower quartile–upper quartile). Significance was determined by unpaired Student's $t$ test, $\chi^2$, or non-parametric Mann–Whitney $U$ test.
Associations of enrolled parameters with ovarian PTX3 levels in PCOS

Table 2 shows the univariated relationships between the ovarian PTX3 level and several anthropometric, endocrine, and metabolic parameters. In the whole sample of PCOS and control subjects, correlation analysis revealed that the PTX3 level in FF was positively associated with the existence of PCOS ($R = 0.534, P < 0.001$), cycle length ($R = 0.425, P < 0.001$), basal LH to FSH ratio ($R = 0.398, P < 0.001$), and TT ($R = 0.475, P < 0.001$) in serum, AFC ($R = 0.467, P < 0.001$), ovarian insulin level ($R = 0.179, P = 0.010$), and ovarian hyperandrogenism ($R = 0.616$ for androstenedione; $R = 0.664$ for TT; $R = 0.668$ for FAI, all $P < 0.001$). And it was inversely associated with the basal serum PRL ($R = -0.180, P = 0.010$) and ovarian SHBG ($R = -0.156, P = 0.026$) (Table 2). However, no relationships were observed between the ovarian PTX3 level and age, BMI, duration of infertility, parity, basal serum DHEA-S and $E_2$ levels, COH parameters, and fertilization rate.

The multivariable associations between follicular PTX3 with possible variables are displayed in Table 3. The PTX3 level in the ovary was pronouncedly associated with the existence of PCOS (95% CI = 3.704–8.711), serum LH to FSH ratio on the third day of menstrual cycles (95% CI = 1.704–4.898), and ovarian androstenedione (95% CI = 0.600–0.846). In a multivariable regression model, the associations of ovarian PTX3 with menstrual cycle length, basal PRL, TT, AFC, and ovarian TT, FAI, SHBG, and insulin levels were no longer significant.

Discussion

In the present study, we found that the ovarian PTX3 is increased in non-obese PCOS women. In addition, the existence of PCOS, serum basal LH/FSH ratio, and high levels of ovarian androstenedione were strongly associated with the ovarian PTX3 level. To our knowledge, this study, for the first time, explored the ovarian PTX3 level in PCOS women and investigated the relationships between ovarian PTX3 level and other hormones.

Up to now, there were several studies investigating serum PTX3 level in PCOS, but the association between PTX3 and PCOS remains uncertain. Among these studies, serum PTX3 level in PCOS women was found to be lower [12, 13], higher [14, 17], or comparable [18] to that of non-PCOS women. In contrast to the short pentraxin, CRP, which is predominantly produced in the liver, PTX3 is synthesized in response to local inflammatory stimuli by a variety of cells, and ovarian follicular cells have innate immune capabilities that modulate their endocrine function [19]. Our previous study has found that the granulosa cells from PCOS women had higher expression of...
PTX3 than the non-PCOS women [4]. So it is of great significance to evaluate the PTX3 level in the ovarian environment. Mean PTX3 level in the follicle was 10.18 ± 0.47 ng/mL in the normal ovulating women, which is similar to the finding of Alessio et al. [20]. The mean concentration of follicular PTX3 in PCOS women was 19.76 ± 1.17 ng/mL, which was clearly higher compared to normal ovulating controls. Studies in mice have revealed that \textit{Ptx3} mRNA expression starts 2 h after injection of hCG, peaks at 6 h, and declines thereafter [15], coinciding with matrix deposition by cumulus cells and cumulus expansion [21]. It might be hypothesized that the variability in time between hCG injection and ovum pick-up could account for elevated follicular PTX3 in PCOS women. But oocyte retrieval is usually performed at 36 h after hCG administration, so our results provide a basis for pursuing studies on the innate immunity in the pathogenesis of PCOS, and PXT3 might also have specific diagnostic and immunologic therapeutic value in PCOS.

We failed to find any significant association between fertilization rate and follicular concentration of PTX3. However, the fertilization rate here refers to the retrieved oocytes of one woman, not the oocytes that come from the examined FF, so it is more meaningful to perform in vitro study to evaluate the effect of PTX3 on fertilization. There is a constant state of chronic low-grade inflammation in obesity and insulin resistance [22]. Samples from the non-obese women were selected in our study to minimize the influences of obesity and metabolic disturbances on inflammatory status. The uncertain association between plasma PTX3 level and metabolic disturbances has been discussed in several studies [13, 14]. Previous studies related to male subjects have reported inverse link between plasma PTX3 and fat mass [23], BMI [24], and waist circumference [24], while positive correlation between PTX3 levels and BMI as well as visceral obesity in PCOS was observed [14]. A recent study carried out by Katarzyna et al. also showed a positive correlation between circulating PTX3 levels and BMI values and fat percentage in women with PCOS, while the correlation was negative in non-PCOS women [17]. It was reported that PTX3 mRNA expression is up-regulated in visceral adipose tissue in obesity, whereas the plasma PTX3 levels inversely correlated with insulin secretion [25]. The discrepancies of these studies are not easily explained. In our study, the enrolled PCOS women had higher BMI and ovarian insulin level than the control, but further association analysis indicated that ovarian PTX3 level was not correlated with BMI or ovarian insulin level among the enrolled subjects. Possible explanation of this finding is the concentration of BMI that varies from 18.5 to 25. Most PCOS subjects from other studies are overweight or obese with higher BMI or fat percentage and the enrolled subjects in our study compromised Chinese women with lower BMI values. Since PTX3 can be secreted by follicular cells and the existence of blood-follicle barrier that separates FF from blood capillaries [26], and we have excluded the obese women during the study, it is reasonable to have such discord with that in the circulation.

Hyperandrogenism, especially the excessive androgen production by the ovaries, is the core pathophysiologic feature of PCOS [4, 27]. The enrolled PCOS women in our study showed higher androgen levels both in the circulation and ovary. Ibrahim et al. had reported that hyperandrogenism might be related to the low-grade chronic inflammatory state in PCOS women [28]. Among the enrolled subjects, we found significantly positive correlations between ovarian PTX3 level and endocrine disturbances of this condition, including higher ovarian and circulating androgen levels. Further regression analysis revealed that the correlations of PTX3 level in follicle with menstrual cycle length, day3 PRL, day3 TT, AFC in FF, FAI in FF, SHBG in FF, insulin in FF

| Variable | Unstandardized coefficients | Standardized coefficients | $P$ value (95% CI) |
|----------|-----------------------------|---------------------------|-------------------|
| Constant | -2.253                      | 0.140                     | (−5.252–0.747)    |
| Existence of PCOS | 6.207                      | 0.305                     | (3.704–8.711)    |
| Day 3 LH/FSH | 3.301                      | 0.231                     | (1.704–4.898)    |
| Androstenedione in FF | 0.723                      | 0.539                     | (0.600–0.846)    |
| Adjusted $R^2$ | 0.566                       |                           |                   |
| $P$ value of the model | < 0.001                      |                           |                   |
| Std. error of the estimate | 6.383                       |                           |                   |

These factors were adjusted in the multivariate regression analysis: menstrual cycle length, day3 PRL, day3 TT, AFC in FF, FAI in FF, SHBG in FF, insulin in FF.
in the theca cells in ovarian follicle [2], thus inducing hyperandrogenism both in the circulation and ovary. The remarkable female predominance of autoimmune diseases has suggested the immunosuppressive effects of androgens [29], while other investigators reported a direct proinflammatory effect of androgens on mononuclear cell [30, 31]. Despite a documented role of androgen as an immunoregulator with organ-specific manner, the potential role of hyperandrogenism on the immune response, especially innate immune response of ovary, has never been fully illustrated. PCOS is characterized by a chronic inflammatory state both in circulation [28, 32] and ovaries [33]. Ovary acts as the main androgen supplier in women, and is also an androgen-sensitive tissue [34]. Studies have indicated that androgen excess in vivo and in vitro induces a proinflammatory response in PCOS women [35, 36]. In our study, the univariable excess in vivo and in vitro induces a proinflammatory causation of elevated PTX3 in the follicle.

PTX3 finding suggests that ovarian hyperandrogenism might be the cause of elevated PTX3 in the follicle. PtX3 expression in the follicle cells is regulated by growth differentiation factor 9, which is regulated by androgen/androgen receptor [37]. The RNA-seq data indicated the upregulation of PTX3 in follicle cells from PCOS women is associated with hyperandrogenism [4]. However, there is no available data on the direct effect of androgens on PTX3 production. Further studies are warranted to clarify the potential role of endocrine mediators in the development of higher PTX3 in the ovary.

There are several limitations and considerations with regard to the present study. All the enrolled subjects were undergoing assisted reproductive medicine and all the samples were collected after some drug administration. Secondly, the subjects enrolled in our study were non-obese, so it is worth further verification in both obese and non-obese subjects, or other ethnic groups should be undertaken with caution. What’s more, the enrolled samples were all from luteinized follicles. Therefore, it is of significance to further confirm our findings in unstimulated and non-luteinized follicular fluid, and also this can be further carried out in animal study.

Acknowledgements The authors would like to thank the laboratory staff for the support in maintaining and analyzing the samples and they are also grateful to all women who participated in this study.

Authors’ contribution J.P., H.H., and L.J. contributed to design of the study and drafted the manuscript; J.P. and C.Z. did the experiment and were involved in the acquisition of data. Z.Z., Z.Y., and T.D. collected the sample and revised the article.

Funding This study was supported by Natural Science Foundation of China (No. 81801411, 81871140), Shanghai Pujiang Program (2020PJJD077), Zhejiang Provincial Natural Science Foundation of China (No. LQ18H040005), Research Project of Shanghai Municipal Health Commission (No. 2020Y0234), Clinical Research Plan of SHDC (No. SHDC 2020CE1008A), Science and Technology Commission of Shanghai Municipality (No. 20221900400), and China Scholarship Council (No. 201808330159).

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Ricardo A. Criteria, prevalence, and phenotypes of polycystic ovarian syndrome. Fertil Steril. 2016;106(1):6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003.
2. Azziz R, Carmina E, Chen Z, Dunia F, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2. https://doi.org/10.1038/nrdp.2016.57.
3. Azziz R. PCOS in 2015: new insights into the genetics of polycystic ovary syndrome. Nat Rev Endocrinol. 2016;12(2):74–5. https://doi.org/10.1038/nrendo.2016.9.
4. Pan J-X, Tan Y-J, Wang F-F, Hou N-N, Xiang Y-Q, Zhang J-Y, et al. Aberrant expression and DNA methylation of lipid metabolism genes in PCOS: a new insight into its pathogenesis. Clin Epigenetics. 2018;10(1):6. https://doi.org/10.1186/s13148-018-0442-y.
5. Paliourea E, Diamanti-Kandarakis E. Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). Rev Endocr Metab Disord. 2015;16(4):365–71. https://doi.org/10.1007/s11154-016-9326-7.
6. group TREA-sPcW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098.
7. Subramaniam AG, Joseph A, Gupta A, Krishna MB, Laloraya M, Pillai SM. Reduced Tregs in peripheral blood of PCOS patients – a consequence of aberrant Il2 signaling. J Clin Endocrinol Metab. 2015;100(1):282–92. https://doi.org/10.1210/jc.2014-2401.
8. Xiao N, He K, Gong F, Xie Q, Peng J, Su X, et al. Altered subsets and activities of B lymphocytes in polycystic ovary syndrome. J Allergy Clin Immunol. 2019;143(5):1943–5. https://doi.org/10.1016/j.jaci.2019.01.007.
9. Garlanda C, Hirsch E, Bozza S, Salustri A, De Aceti M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420(6912):182–6. https://doi.org/10.1038/nature01195.
10. Camaioni A, Klinger FG, Campagnolo L, Salustri A. The influence of pentraxin 3 on the ovarian function and its impact on fertility.
Front Immunol. 2018;9:2808. https://doi.org/10.3389/fimmu.2018.02808.

11. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, et al. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Mol Endocrinol. 2002;16(6):1154–67. https://doi.org/10.1210/mend.16.6.0859.

12. Tosi F, Di Sarra D, Bonin C, Zambotti F, Dall’Alda M, Fiers T, et al. Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. Eur J Endocrinol. 2014;170(3):401–9. https://doi.org/10.1530/EJE-13-0761.

13. Sahin FK, Sahin SB, Balik G, Ural UM, Teken YB, Cure MC, et al. Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity? Int J Clin Exp Med. 2014;7(10):3512. https://doi.org/10.14740/ijcem.v7i10.119513590.2011.652719.

14. Aydogdu A, Tasci I, Tapan S, Basaran Y, Aydogan U, Merc C, et al. High plasma levels of long pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(9):722–5. https://doi.org/10.3109/09513590.2011.652719.

15. Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development. 2004;131(7):1577–86. https://doi.org/10.1242/dev.01056.

16. McKenzie LJ, Pangas SA, Carson SA, Kovanci O, Cisneros P, Kovanci E, et al. Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. Mol Endocrinol. 2002;16(6):1154–67. https://doi.org/10.1210/mend.16.6.0859.

17. Wyskida K, Franik G, Chorowska P, Pohl N, Markuszewski L, Owczarek A, et al. Pentraxin 3 levels in young women with and without polycystic ovary syndrome. Eur J Endocrinol. 2014;170(3):401–9. https://doi.org/10.1530/EJE-13-0761.

18. Güdücü N, Görmüştüz P, Pohl N, Markuszewski L, Owczarek A, et al. Pentraxin 3 levels in young women with and without polycystic ovary syndrome (PCOS) in relation to the nutritional status and systemic inflammation. Int J Endocrinol. 2020;2020:1380176. https://doi.org/10.1155/2020/1380176.

19. Güdücü N, Görmüştüz P, Alp E, Kavak ZN. Dünder İ. Reciprocal action of pentraxin-3 and Crp in women with polycystic ovary syndrome. European J Inflamm. 2014;12(1):161–6. https://doi.org/10.1177/1721727X1401200115.

20. Herath S, Williams EJ, Lilly ST, Gilbert RO, Dobson H, Bryant CE, et al. Ovarian follicular cells have innate immune capabilities that modulate their endocrine function. Reproduction. 2007;134(5):933–42. https://doi.org/10.1530/rep-07-0229.

21. Saliel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1–4. https://doi.org/10.1172/JCI92035.

22. Bosutti A, Malaponte G, Zanetti M, Castellino P, Heer M, Guarnieri G, et al. Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. J Clin Endocrinol Metab. 2008;93(8):3226–9. https://doi.org/10.1210/jc.2007-1684.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.